Related Experiment Video
Updated: Jul 10, 2026
04:12
Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
Published on: January 19, 2024
Methotrexate in dermatology
Carolyn A Bangert1, Melissa I Costner
1Department of Dermatology, University of Texas Medical School at Houston, Houston, Texas 77030, USA. Carolyn.Bangert@utsouthwestern.edu
Dermatologic Therapy
|November 1, 2007
Summary
Methotrexate, a folic acid analog, is a long-standing treatment for inflammatory skin diseases. New research explores its anti-inflammatory effects and genetic factors to optimize therapy and predict side effects.
Area of Science:
- Dermatology
- Pharmacology
- Immunology
Background:
- Methotrexate is a folic acid analog with over 40 years of use in dermatology for cutaneous diseases.
- It possesses antiproliferative and anti-inflammatory properties, the latter linked to adenosine pathways.
Purpose of the Study:
- To review methotrexate's pharmacokinetics, administration, dosing, side effects, and interactions.
- To provide practical guidelines for methotrexate therapy initiation and adjustment.
- To summarize emerging research on its mechanism of action and future therapeutic potential.
Main Methods:
- Literature review of existing studies on methotrexate.
- Analysis of pharmacokinetic and pharmacodynamic data.
- Synthesis of current research on mechanisms and genetic variations.
Main Results:
- Established efficacy and safety profile of methotrexate in various dermatological conditions.
- Identified anti-inflammatory mechanisms beyond antiproliferation, involving adenosine.
- Highlighted the role of genetic variations in predicting treatment response and adverse events.
Conclusions:
- Methotrexate remains a cornerstone therapy for numerous skin diseases.
- Understanding its adenosine-related anti-inflammatory effects and genetic factors can personalize treatment.
- Further research promises optimized methotrexate therapy and improved patient outcomes.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:23Skin Diseases and Disorders
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...